Bentracimab is designed to reverse the antiplatelet activity of ticagrelor. Credit: aodaodaodaod on Shutterstock.com.

Speciality pharmaceutical company SERB Pharmaceuticals has acquired exclusive US rights for bentracimab from SFJ Pharmaceuticals.

SFJ Pharmaceuticals will lead the ongoing clinical trial of bentracimab.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In partnership with SERB Pharmaceuticals, the company will also file a biologics licence application (BLA) to the US Food and Drug Administration (FDA) later this year.

The new monoclonal antibody fragment bentracimab is designed to reverse the antiplatelet activity of ticagrelor, a reversible oral P2Y12 platelet inhibitor.

Marketed as Brilinta by AstraZeneca, ticagrelor has been developed for heart attack or stroke patients and those with acute coronary syndromes and coronary artery disease (CAD).

Subject to receiving FDA approval, bentracimab will allow these patients to benefit from the antithrombotic effect of ticagrelor, helping to reduce the death risk and preventing vascular events.

SERB Pharmaceuticals executive chairman Jeremie Urbain stated: “The acquisition of bentracimab marks a significant step in our strategy to grow through investment in innovative biologic products for critical care conditions and leverages our existing commercial and technical capabilities.

“We’re excited to partner with SFJ, recognised leaders in late-stage drug development, to bring this life-saving medicine to healthcare professionals and the patients they treat.”

Interim analysis from the ongoing Phase III REVERSE-IT trial showed that bentracimab quickly and sustainably reversed ticagrelor’s antiplatelet effects.

 It was found to be well-tolerated, with only minor adverse events observed.

The US FDA granted breakthrough therapy designation to bentracimab in 2019.